Go Pro
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel Free IRD Stock Alerts

Opus Genetics (IRD) News Today

Opus Genetics logo
$5.18 -0.10 (-1.89%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$5.24 +0.07 (+1.25%)
As of 09/18/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Opus Genetics Latest News

Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRD
September 17 at 3:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-takes-136-million-position-in-opus-genetics-inc-ird-2026-09-17/
Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?
September 16, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/opus-genetics-ird-reports-five-early-bird-1-responses-is-phase-3-planning-justified-1836045/
Opus Genetics consensus price target increased 21.47% to $12.98
September 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/economy/opus-genetics-consensus-price-target-increased-21-47-to-12-98/ar-AA2cjIBD
Wedbush Forecasts Strong Price Appreciation for Opus Genetics (NASDAQ:IRD) Stock
September 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31018267
Opus Genetics (NASDAQ:IRD) Sees Unusually-High Trading Volume After Analyst Upgrade
September 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31017732
Opus Genetics (NASDAQ:IRD) Stock Price Expected to Rise, Oppenheimer Analyst Says
September 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31016327
Opus Genetics (NASDAQ:IRD) Earns Buy Rating from HC Wainwright
September 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31016314
Opus Genetics (NASDAQ:IRD) Earns Buy Rating from BTIG Research
September 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31016307
Opus Genetics Sees Unusually Large Options Volume (NASDAQ:IRD)
September 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31016287
Traders Purchase High Volume of Call Options on Opus Genetics (NASDAQ:IRD)
September 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31016290
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pyxis Oncology (PYXS) and Opus Genetics (IRD)
September 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IRD/pressreleases/4540591/analysts-opinions-are-mixed-on-these-healthcare-stocks-pyxis-oncology-pyxs-and-opus-genetics-ird/
Opus Genetics (NASDAQ:IRD) Sees Large Volume Increase After Analyst Upgrade
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-opus-genetics-nasdaq-ird-sees-large-volume-increase-after-analyst-upgrade-2026-09-10/
Opus Genetics (NASDAQ:IRD) Given New $13.00 Price Target at Wedbush
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-opus-genetics-nasdaq-ird-given-new-1300-price-target-at-wedbush-2026-09-10/
Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating
September 10, 2026  |  marketscreener.comM
Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating
September 9, 2026  |  marketscreener.comM
Clinical Catalysts Drive Biotech Movers: Opus Genetics, Quantum & More
September 9, 2026  |  rttnews.comhttps://www.rttnews.com/3689702/clinical-catalysts-drive-biotech-movers-opus-genetics-quantum-more.aspx
IRD stock hits over 5-year highs – Opus Genetics experimental therapy shows early promise in retinal diseases trial
September 9, 2026  |  msn.comhttps://www.msn.com/en-in/health/diseases-and-conditions/ird-stock-hits-over-5-year-highs-opus-genetics-experimental-therapy-shows-early-promise-in-retinal-diseases-trial/ar-AA2bTjsg
Oppenheimer Issues Positive Forecast for Opus Genetics (NASDAQ:IRD) Stock Price
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-oppenheimer-issues-positive-forecast-for-opus-genetics-nasdaq-ird-stock-price-2026-09-09/
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial - Slideshow
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944598-opus-genetics-inc-ird-discusses-topline-results-from-cohort-1-of-best1-phase-i-ii-gene
HC Wainwright Reiterates Buy Rating for Opus Genetics (NASDAQ:IRD)
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hc-wainwright-reiterates-buy-rating-for-opus-genetics-nasdaq-ird-2026-09-09/
Opus Genetics Reports Positive OPGx-BEST1 Data; Plans Potential Phase 3 Trial In 2027
September 9, 2026  |  rttnews.comhttps://www.rttnews.com/3689587/opus-genetics-reports-positive-opgx-best1-data-plans-potential-phase-3-trial-in-2027.aspx
Opus Genetics Reports Vision Improvement in Phase 1/2 OPGx-BEST1 Trial
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/opus-genetics-reports-vision-improvement-120249070.html
Opus Genetics reports positive OPGx-BEST1 phase 1/2 data, targets potential phase 3 dosing in 2027
September 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/opus-genetics-reports-positive-opgx-best1-phase-1-2-data-targets-potential-phase-3-dosing-in-2027/ar-AA2bTdgy
Opus Genetics (NASDAQ:IRD) Given "Buy" Rating at BTIG Research
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-opus-genetics-nasdaq-ird-given-buy-rating-at-btig-research-2026-09-09/
Opus Genetics (NASDAQ:IRD) Hits New 12-Month High - Here's What Happened
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-opus-genetics-nasdaq-ird-hits-new-12-month-high-heres-what-happened-2026-09-09/
Stock Traders Purchase High Volume of Opus Genetics Call Options (NASDAQ:IRD)
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-stock-traders-purchase-high-volume-of-opus-genetics-call-options-nasdaq-ird-2026-09-09/
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
September 9, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61690048/gene-therapy-at-lower-dose-shows-vision-improvements-opus-genetics-says?utm_source=snapi
Chardan Capital Reaffirms "Buy" Rating for Opus Genetics (NASDAQ:IRD)
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-chardan-capital-reaffirms-buy-rating-for-opus-genetics-nasdaq-ird-2026-09-09/
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358458/0/en/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027.html
Opus Genetics (NASDAQ:IRD) CFO Sells $127,120.00 in Stock
September 9, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ird-insider-buying-and-selling-2026-09-09/
Robert Gagnon Sells 28,000 Shares of Opus Genetics (NASDAQ:IRD) Stock
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-robert-gagnon-sells-28000-shares-of-opus-genetics-nasdaq-ird-stock-2026-09-08/
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Rating of "Moderate Buy" from Analysts
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-opus-genetics-inc-nasdaq-ird-receives-average-rating-of-moderate-buy-from-analysts-2026-09-06/
BlackRock Inc. Takes $12.81 Million Position in Opus Genetics, Inc. $IRD
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-takes-1281-million-position-in-opus-genetics-inc-ird-2026-09-05/
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and TScan Therapeutics (TCRX)
September 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4432176/analysts-offer-insights-on-healthcare-companies-opus-genetics-ird-and-tscan-therapeutics-tcrx/
Missed Opus Genetics' 130% Run? The Story Isn't Over Yet
September 3, 2026  |  rttnews.comhttps://www.rttnews.com/3688196/missed-opus-genetics-130-run-the-story-isn-t-over-yet.aspx
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3354959/0/en/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences.html
Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/opus-genetics-shares-rise-5-125927253.html
Susquehanna International Group LLP Sells 707,886 Shares of Opus Genetics, Inc. $IRD
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-susquehanna-international-group-llp-sells-707886-shares-of-opus-genetics-inc-ird-2026-09-01/
Nantahala Capital Management LLC Makes New Investment in Opus Genetics, Inc. $IRD
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nantahala-capital-management-llc-makes-new-investment-in-opus-genetics-inc-ird-2026-08-29/
Trails Edge Capital Partners LP Takes $11.28 Billion Position in Opus Genetics, Inc. $IRD
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-trails-edge-capital-partners-lp-takes-1128-billion-position-in-opus-genetics-inc-ird-2026-08-26/
ADAR1 Capital Management LLC Takes $7.33 Million Position in Opus Genetics, Inc. $IRD
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-adar1-capital-management-llc-takes-733-million-position-in-opus-genetics-inc-ird-2026-08-26/
Opus Genetics Target of Unusually Large Options Trading (NASDAQ:IRD)
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-opus-genetics-target-of-unusually-large-options-trading-nasdaq-ird-2026-08-25/
Analysts Are Bullish on These Healthcare Stocks: Evaxion Biotech (EVAX), Opus Genetics (IRD)
August 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/EVAX/pressreleases/3986075/analysts-are-bullish-on-these-healthcare-stocks-evaxion-biotech-evax-opus-genetics-ird/
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/19/3347961/0/en/opus-genetics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Opus Genetics (IRD) Gets a Buy from RBC Capital
August 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IRD/pressreleases/3735070/opus-genetics-ird-gets-a-buy-from-rbc-capital/
Cantor Fitzgerald Sticks to Their Buy Rating for Opus Genetics (IRD)
August 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IRD/pressreleases/3736529/cantor-fitzgerald-sticks-to-their-buy-rating-for-opus-genetics-ird/
Opus Genetics Inc.
August 6, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/ird/stock-grader?gaa_n=AWEtsqdwlLI99OzShxt1i_FC2NpczRtYeet_D8BTdAA0ONrHhYhgETaw3K9G&gaa_ts=698e4276
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/opus-genetics-announces-financial-results-110000109.html
Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/opus-genetics-completes-enrollment-phase-122437977.html
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337367/0/en/opus-genetics-completes-patient-enrollment-in-registrational-phase-3-trial-of-opgx-lca5-for-lca5-associated-inherited-retinal-disease.html

Opus Genetics Media Mentions By Week

Opus Genetics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IRD
News Sentiment
▼
1.33

0.56
▲
Average
Healthcare
News Sentiment

Opus Genetics News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IRD Articles
This Week
▼
3

6
▲
IRD Articles
Average Week

Opus Genetics Trends on MarketBeat

This week vs. last week
New Followers
3
+200%
Searches
2
-67%
Page Views
2,825
-20%
Get Opus Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
News and Trends Tools

MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Opus Genetics dated 9/17/2026.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
“Elon’s nightmare” could fund your retirement
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
You’ve never seen anything like this before
For centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...
Porter & Company | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel